Taking on a Monster

Egan, Mary Ellen
November 2004
Forbes Global;11/15/2004, Vol. 7 Issue 20, p64
Offers a look on two prospective drugs for brain cancer, IL-13 and Transmid, that are giving patients a new lease on life as of 20014. Background on the case of David Herbert, a former pilot diagnosed with glioblastoma multiforme; Makers of IL-13 and Transmid; Number of U.S. citizens diagnosed with glioblastoma multiformes; Mechanism of action of the two drugs.


Related Articles

  • Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety. Candolfi, Marianela; Kroeger, Kurt M.; Muhammad, A. K. M. G.; Yagiz, Kader; Farrokhi, Catherine; Pechnick, Robert N.; Lowenstein, Pedro R.; Castro, Maria G. // Current Gene Therapy;Oct2009, Vol. 9 Issue 5, p409 

    Glioblastoma multiforme (GBM) is the most common primary brain cancer in adults. Despite significant advances in treatment and intensive research, the prognosis for patients with GBM remains poor. Therapeutic challenges for GBM include its invasive nature, the proximity of the tumor to vital...

  • Carboxyamidotriazole Orotate and Cytotoxic Chemotherapy have a Synergistic Effect on Tumor Inhibition in Glioblastoma and Colon Xenograft Mouse Models. Karmali, Rashida A.; Maxuitenko, Yulia; Gorman, Greg; Page, John G. // Cancer Therapy;2011, Vol. 8, p71 

    The purpose of this study was to evaluate the antitumor efficacy of carboxyamidotriazole orotate (CTO) alone or in combination with cytotoxic chemotherapy in glioblastoma and colon cancer xenograft mouse models. CTO targets VEGF and PI3K via Ca++ signaling pathways. Combination therapy with VEGF...

  • Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Sanchez-Perez, Luis; Suryadevara, Carter M; Choi, Bryan D; Reap, Elizabeth A; Sampson, John H // OncoImmunology;Jul2014, Vol. 3 Issue 7, pN.PAG 

    First-line chemotherapy to combat primary malignant brain cancer is often accompanied by lymphopenic immunologic deficiency. Although counterintuitive, chemotherapy-induced lymphopenia can provide excellent host conditioning that may actually be leveraged to potentiate antitumor immunotherapy....

  • Complete Remission and Long Term Survival in Recurrent Malignant Glioblastoma Treated with Fotemustine Monotherapy: A Case Report. Cerullo, Carmine; Fonte, Carla; Muto, Andrea; Vannini, Agnese; Rediti, Mattia; Rangan, Sheila; Bordi, Lorenzo; Neri, Bruno // Journal of Cancer Therapy;Apr2013, Vol. 4 Issue 2, p584 

    Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. Conventional therapies are considered palliative and long-term progression-free survival remains low for most GBM patients even after surgical excision, concomitant radiotherapy and/or chemotherapy with nitrosoureas or...

  • Rethinking immunotherapy for brain cancers in the light of cancer complexity. Grizzi, Fabio; Di Ieva, Antonio // Indian Journal of Medical Research;May2013, Vol. 137 Issue 5, p871 

    The article discusses the search for new and more targeted therapeutic options for brain cancers despite available treatments including surgical resection, radiation therapy and cytotoxic chemotherapy. The authors attribute the situation to the incurability of brain cancers. They cite the...

  • Brain cancer study to begin in Tarrant area. Newton, Teresa // Business Press;02/27/98, Vol. 10 Issue 44, p3 

    Recognizes Tarrant County in Forth Worth, Texas as the first United States site for a brain cancer treatment study. Participation of Columbia Plaza Medical Center in the study for malignant gliomas; Sponsor of the study; Results of past studies on the effectiveness of Gliadel Wafer against...

  • The TRAIL Sensitization Effect of Substituted Triazolyl Curcumin Mimics Against Brain Cancer Cells. Daeho Kwon; Sangtae Oh; Ji-Hye Park; Seoul Lee; Seokjoon Lee // Bulletin of the Korean Chemical Society;2014, Vol. 35 Issue 11, p3339 

    The article discusses the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) sensitization effect of substituted triazolyl curcumin against brain cancer cells. Topics covered include the effectiveness of the co-treatment with a TRAIL and its sensitizer against glioblastoma...

  • Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment. Schuessler, Andrea; Walker, David G; Khanna, Rajiv // OncoImmunology;Jun2014, Vol. 3 Issue 6, pN.PAG 

    Glioblastoma multiforme (GBM) has a very poor prognosis, despite multimodal therapy including surgery, radiation and chemotherapy. A novel adoptive immunotherapy that exploits the presence of cytomegalovirus antigens in malignant brain cancer cells has been shown to be safe and elicit potential...

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. Stupp, Roger; Mason, Warren P.; van den Bent, Martin J.; Weller, Michael; Fisher, Barbara; Taphoorn, Martin J.B.; Belanger, Karl; Brandes, Alba A.; Marosi, Christine; Bogdahn, Ulrich; Curschmann, Jürgen; Janzer, Robert C.; Ludwin, Samuel K.; Gorlia, Thierry; Allgeier, Anouk; Lacombe, Denis; Cairncross, J. Gregory; Eisenhauer, Elizabeth; Mirimanoff, René O. // New England Journal of Medicine;3/10/2005, Vol. 352 Issue 10, p987 

    Background: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics